Outeiro, Tiago Fleming

Home >> Publications >> Author >> Outeiro, Tiago Fleming >> Page 3
Feature image not available
08.03.2024

Synphilin-1 as a modulator of aSyn assembly

Authors Lázaro DF, Amen T, Gerhardt E, Santos PI, Milovanovic D, Höglinger G, Outeiro TF Journal BioRxiv Citation bioRxiv 2024.03.05.583522. Abstract Alpha-synuclein (aSyn) is an intrinsically disordered protein that undergoes phase-separation and is associated with several neurodegenerative conditions. However, the function and the pathological role of aSyn are still elusive.
Learn More
Feature image not available
06.03.2024

Towards a biological diagnosis of PD

Authors Chopra A, Lang AE, Höglinger G, Outeiro TF Journal Parkinsonism & Related Disorders Citation Parkinsonism Relat Disord. 2024 Mar 6:106078. Abstract Since the original description by James Parkinson, Parkinson’s disease (PD) has intrigued us for over 200 years. PD is a progressive condition that is incurable so far, and
Learn More
Feature image not available
28.02.2024

Inhibition of 26S proteasome activity by α-synuclein is mediated by the proteasomal chaperone Rpn14/PAAF1

Authors Galka D, Ali TT, Bast A, Niederleithinger M, Gerhardt E, Motosugi R, Sakata E, Knop M, Outeiro TF, Popova B, Braus GH   Journal Aging Cell   Citation Aging Cell. 2024 Feb 28:e14128.   Abstract Parkinson’s disease (PD) is characterized by aggregation of α-synuclein (α-syn) into protein inclusions in
Learn More
Feature image not available
01.02.2024

A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria

Authors Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE Journal The Lancet. Neurology Citation Lancet Neurol. 2024 Feb;23(2):191-204. Erratum in: Lancet Neurol. 2024 Mar;23(3):e7. Abstract With the hope that disease-modifying treatments could target the molecular basis of Parkinson’s disease, even
Learn More
Feature image not available
09.01.2024

Substitution of Met-38 to Ile in γ-synuclein found in two patients with amyotrophic lateral sclerosis induces aggregation into amyloid

Authors Aubrey LD, Ninkina N, Ulamec SM, Abramycheva NY, Vasili E, Devine OM, Wilkinson M, Mackinnon E, Limorenko G, Walko M, Muwanga S, Amadio L, Peters OM, Illarioshkin SN, Outeiro TF, Ranson NA, Brockwell DJ, Buchman VL, Radford SE Journal Proceedings of the National Academy of Sciences of the United
Learn More
Feature image not available
08.01.2024

Uncovering potential diagnostic and pathophysiological roles of α-synuclein and DJ-1 in melanoma

Authors Quesnel A, Martin LD, Tarzi C, Lenis VP, Coles N, Islam M, Angione C, Outeiro TF, Khundakar AA, Filippou PS Journal Cancer Medicine Citation Cancer Med. 2024 Jan 8. Abstract Background Melanoma, the most lethal skin cancer type, occurs more frequently in Parkinson’s disease (PD), and PD is more
Learn More
Feature image not available
19.10.2023

PrP meets alpha-synuclein: Molecular mechanisms and implications for disease

Authors Vieira TCRG, Barros CA, Domingues R, Outeiro TF Journal Journal of Neurochemistry Citation J Neurochem. 2023 Oct 19. Abstract The discovery of prions has challenged dogmas and has revolutionized our understanding of protein-misfolding diseases. The concept of self-propagation via protein conformational changes, originally discovered for the prion protein (PrP),
Learn More
Feature image not available
11.10.2023

Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria

Authors Klein AD, Outeiro TF Journal Nature Communications Citation Nat Commun. 2023 Oct 11;14(1):6383. Abstract β-Glucocerebrosidase (GCase) mutations lead to glucosylceramide build-up in the lysosome, impacting α-synuclein aggregation and autophagy. Recently, Baden and colleagues found GCase in mitochondria, supporting mitochondrial complex I function and energy metabolism. We believe the newly
Learn More
Feature image not available
03.09.2023

Increased alpha-synuclein and neuroinflammation in the substantia nigra triggered by systemic inflammation are reversed by targeted inhibition of the receptor for advanced glycation end products (RAGE).

Authors Peixoto DO, Bittencourt RR, Gasparotto J, Kessler FGC, Brum PO, Somensi N, Girardi CS, Dos Santos da Silva L, Outeiro TF, Moreira JCF, Gelain DP Journal Journal of Neurochemistry Citation J Neurochem. 2023 Sep 3. Abstract The receptor for advanced glycation end products (RAGE) is a protein of the
Learn More
Feature image not available
30.08.2023

Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson’s Disease

Authors Brembati V, Faustini G, Longhena F, Outeiro TF, Bellucci A Journal International Journal of Molecular Sciences Citation Int. J. Mol. Sci. 2023, 24(17) Abstract Parkinson’s disease (PD) pathology is characterized by the loss of dopaminergic neurons of the nigrostriatal system and accumulation of Lewy bodies (LB) and Lewy neurites
Learn More
X

Open Positions

EN DE
X
X